{"id":3381,"date":"2022-02-02T23:56:00","date_gmt":"2022-02-02T23:56:00","guid":{"rendered":"http:\/\/staging.grindeks.eu\/grindeks-group-closes-2021-with-record-high-turnover-of-eur-231-1-million\/"},"modified":"2022-09-05T12:48:31","modified_gmt":"2022-09-05T12:48:31","slug":"grindeks-koncerns-2021-gadu-nosledz-ar-rekordlielu-2311-milj-eiro-apgrozijumu","status":"publish","type":"post","link":"https:\/\/grindeks.com\/lv\/grindeks-koncerns-2021-gadu-nosledz-ar-rekordlielu-2311-milj-eiro-apgrozijumu\/","title":{"rendered":"Grindeks koncerns 2021. gadu nosl\u0113dz ar rekordlielu 231,1 milj. eiro apgroz\u012bjumu"},"content":{"rendered":"\n

Grindeks koncerna konsolid\u0113tie, provizoriskie finan\u0161u dati liecina, ka 2021. gadu koncerns nosl\u0113dzis ar rekordlielu apgroz\u012bjumu un pe\u013c\u0146u. \u0160aj\u0101 period\u0101 Grindeks koncerna apgroz\u012bjums sasniedza 231,1 milj. eiro, kas ir par 44,0 milj. eiro vai 24% vair\u0101k nek\u0101 2020. gad\u0101. 2021. gad\u0101 koncerna pe\u013c\u0146a bija 41,0 milj. eiro, kas ir par 22,1 milj. eiro vai 2 reizes vair\u0101k nek\u0101 2020. gad\u0101.<\/p>\n\n\n\n

\nhttps:\/\/www.youtube.com\/watch?v=ungCtl5tctU&feature=emb_title\n<\/div><\/figure>\n\n\n\n

2021. gad\u0101 liel\u0101ko p\u0101rdo\u0161anas apjomu veidoja medikamenti sirds un asinsvadu, k\u0101 ar\u012b centr\u0101l\u0101s nervu sist\u0113mas slim\u012bbu \u0101rst\u0113\u0161anai. Strauju p\u0101rdo\u0161anas k\u0101pumu sasniedza ar\u012b slimn\u012bcu segmenta medikamenti, ko pied\u0101v\u0101 Grindeks meitas uz\u0146\u0113mums Kalceks.<\/p>\n\n\n\n

2021. gad\u0101 koncerns sara\u017eoto produkciju eksport\u0113ja uz 103 valst\u012bm par kop\u0113jo summu 218,7 milj. eiro.<\/p>\n\n\n\n

Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js Dr. chem. Juris Hme\u013c\u0146ickis:<\/strong> \u201c2021. gads Grindeks koncernam ir bijis p\u0101rmai\u0146u gads, kas ir par\u0101d\u012bjis, ka izcila komanda var sasniegt \u013coti daudz. Z\u0101\u013cu kl\u0101sta papla\u0161in\u0101\u0161ana, pacientu vajadz\u012bbu izzin\u0101\u0161ana, jaunu tirgu apguve, z\u0101\u013c\u0101s dom\u0101\u0161anas kurss un v\u0113l daudzas noz\u012bm\u012bgas iniciat\u012bvas ir neapturams dzinulis att\u012bst\u012bbai. Pag\u0101ju\u0161\u0101 gada laik\u0101 es p\u0101rliecin\u0101jos, ka da\u017e\u0101di izaicin\u0101jumi ir p\u0101rvar\u0101mi, pateicoties past\u0101v\u012bgai transfom\u0101cijai, kur katrs komandas dal\u012bbnieks apzin\u0101s savu noz\u012bm\u012bgo lomu kop\u0113ju ideju un m\u0113r\u0137u sasnieg\u0161an\u0101. 231,1 milj. eiro apgroz\u012bjums ir v\u0113sturiski augst\u0101kais Grindeks sasniegums, un es v\u0113los pateikt paldies komandai \u2013 visiem profesion\u0101\u013ciem par paveikto, k\u0101 ar\u012b sadarb\u012bbas partneriem, vesel\u012bbas apr\u016bpes speci\u0101listiem un pacientiem par ilgsto\u0161o uztic\u012bbu mums!\u201d<\/p>\n\n\n\n

Koncerna gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms 2021. gad\u0101 kopum\u0101 bija 219,5 milj. eiro un ir palielin\u0101jies, sal\u012bdzinot ar 2020. gadu, par 45,9 milj. eiro vai par 26%.<\/p>\n\n\n\n

Eiropas Savien\u012bbas un p\u0101r\u0113j\u0101s valst\u012bs gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms 2021. gad\u0101 sasniedza 117,5 milj. eiro, kas ir par 31,6 milj. eiro vai par 37% vair\u0101k nek\u0101 2020. gad\u0101. P\u0101rdo\u0161anas apjoms 2021. gad\u0101, sal\u012bdzinot ar 2020. gadu, Portug\u0101l\u0113 palielin\u0101j\u0101s 29 reizes, Braz\u012blij\u0101 18 reizes, N\u012bderland\u0113 9 reizes, Apvienotajos Ar\u0101bu Emir\u0101tos un Bulg\u0101rij\u0101 4 reizes, Polij\u0101 un Norv\u0113\u0123ij\u0101 3 reizes, Austr\u0101lij\u0101 un \u010cehij\u0101 2 reizes.<\/p>\n\n\n\n

P\u0101rdo\u0161anas apjoms Krievij\u0101, p\u0101r\u0113j\u0101s NVS valst\u012bs un Gruzij\u0101 2021. gad\u0101 veidoja 102,0 milj. eiro, kas ir par 14,3 milj. eiro vai par 16% vair\u0101k nek\u0101 2020. gad\u0101. Sal\u012bdzinot ar 2020. gadu, 2021. gad\u0101 Ukrain\u0101 p\u0101rdo\u0161anas apjoms palielin\u0101j\u0101s par 57%, Baltkrievij\u0101 par 40%, Gruzij\u0101 par 34%, Moldov\u0101 par 33%, Azerbaid\u017e\u0101n\u0101 un Uzbekist\u0101n\u0101 par 23%.<\/p>\n\n\n\n

Grindeks produktu kl\u0101st\u0101 ir m\u016bsdien\u012bgi medikamenti sirds un asinsvadu, centr\u0101l\u0101s nervu sist\u0113mas, onkolo\u0123isko saslim\u0161anu un diab\u0113ta \u0101rst\u0113\u0161anai, savuk\u0101rt meitas uz\u0146\u0113rmums Kalceks pied\u0101v\u0101 medikamentus slimn\u012bcu segmentam. Izstr\u0101d\u0113 \u0161obr\u012bd ir 64 jauni Grindeks un 42 jauni Kalceks medikamenti. 2021. gad\u0101 z\u0101\u013cu re\u0123istr\u0101cijas proced\u016bra tika uzs\u0101kta 10 Grindeks patentbr\u012bviem medikamentiem.<\/p>\n\n\n\n

Kalceks ar\u012b ir uzs\u0101cis 9 jaunu patentbr\u012bvu medikamentu re\u0123istr\u0101cijas decentraliz\u0113t\u0101s proced\u016bras Eiropas Savien\u012bbas valst\u012bs, tai skait\u0101 pirmo \u010detru antibiotisko produktu re\u0123istr\u0101ciju, kas paredz\u0113ts slimn\u012bcu segmentam. \u0145emot v\u0113r\u0101 uz\u0146\u0113muma ilgo pieredzi sterilo z\u0101\u013cu formu izstr\u0101d\u0113, ra\u017eo\u0161an\u0101 un re\u0123istr\u0101cij\u0101, ir uzs\u0101kta pirmo oftalmolo\u0123isko produktu izstr\u0101de.<\/p>\n\n\n\n

Grindeks koncernam \u013coti noz\u012bm\u012bga ir ar\u012b akt\u012bvo farmaceitisko vielu ra\u017eo\u0161ana, kas ir ar\u012b viena no koncerna konkurences priek\u0161roc\u012bb\u0101m. Pa\u0161reiz uz\u0146\u0113mums ra\u017eo 25 akt\u012bv\u0101s farmaceitisk\u0101s vielas. \u0160is segments palielina neatkar\u012bbu no izejvielu ra\u017eot\u0101jiem, t\u0101d\u0113\u013c uz\u0146\u0113mums izstr\u0101d\u0101 36 jaunas akt\u012bv\u0101s farmaceitisk\u0101s vielas. Liel\u0101kais Grindeks akt\u012bvo farmaceitisko vielu eksports tiek veikts uz Eiropas Savien\u012bbas valst\u012bm, Jap\u0101nu, ASV un Austr\u0101liju.<\/p>\n\n\n\n

2021. gad\u0101 Kalceks sasniedza izcilus rezult\u0101tus. P\u0101rdo\u0161anas apjoms strauji pieauga, palielinot gan eksporta valstu skaitu, gan papla\u0161inot produktu kl\u0101stu ar 7 jauniem patentbr\u012bviem medikamentiem. 2021. gada beig\u0101s portfeli veidoja 35 medikamenti. Kalceks produkti 2021. gad\u0101 tika p\u0101rdoti 66,7 milj. eiro apjom\u0101, kas ir par 26,0 milj. eiro vai par 64% vair\u0101k nek\u0101 2020. gad\u0101. Kalceks medikamenti 2021. gad\u0101 tika eksport\u0113ti uz 77 valst\u012bm, un galven\u0101s no t\u0101m bija N\u012bderlande, Meksika, Lielbrit\u0101nija, \u010cehija un Polija.<\/p>\n\n\n\n

Grindeks padomes priek\u0161s\u0113d\u0113t\u0101js Kirovs Lipmans: <\/strong>\u201cNeskatoties uz da\u017e\u0101diem pand\u0113mijas rad\u012btiem \u0161\u0137\u0113r\u0161\u013ciem, p\u0113rn Grindeks koncerna uz\u0146\u0113mumi galveno uzman\u012bbu piev\u0113rsa priorit\u0101t\u0113m \u2013 jauniem produktiem un glob\u0101lai ekspansijai. Esmu patiesi gandar\u012bts par Grindeks koncerna sasniegumiem 2021. gad\u0101. Spo\u017eie rezult\u0101ti \u2013 231,1 milj. eiro apgroz\u012bjums un 41 milj. eiro pe\u013c\u0146a \u2013 skaidri apliecina Grindeks konkur\u0113tsp\u0113ju pasaules ar\u0113n\u0101. Tas ir pamats veiksm\u012bgai att\u012bst\u012bbas projektu norisei.\u201d<\/p>\n\n\n\n

Grindeks 2021. gad\u0101 piev\u0113rsa \u012bpa\u0161u uzman\u012bbu ra\u017eo\u0161anas infrastrukt\u016bras uzlabo\u0161anai un jaunu ra\u017eo\u0161anas iek\u0101rtu uzst\u0101d\u012b\u0161anai, taj\u0101 skait\u0101 notiek Gatavo z\u0101\u013cu formu laboratorijas moderniz\u0101cija.<\/p>\n\n\n\n

Lai ilgtermi\u0146\u0101 turpin\u0101tu pak\u0101penisku un stabilu koncerna izaugsmi, R\u012bg\u0101, Asotes iel\u0101 12 vair\u0101kos posmos tiks b\u016bv\u0113ts Grindeks Inov\u0101cijas centrs. 2021. gad\u0101 tika nosl\u0113gts projekt\u0113\u0161anas l\u012bgums un veikti teritorijas labiek\u0101rto\u0161anas darbi. Inov\u0101ciju centr\u0101 tiks nodro\u0161in\u0101ti komplic\u0113ti akt\u012bvo farmaceitisko vielu ra\u017eo\u0161anas procesi, uzst\u0101d\u012btas m\u016bsdien\u012bgas tehnolo\u0123isk\u0101s iek\u0101rtas un automatiz\u0113ti un energoefekt\u012bvi risin\u0101jumi. Tas b\u016bs liel\u0101kais farm\u0101cijas inov\u0101ciju centrs Baltijas re\u0123ion\u0101.<\/p>\n\n\n\n

https:\/\/infogram.com\/grindeks-koncerns-2021-gada-sasniedz-rekordlielu-apgrozijumu-un-pelnu-1hdw2jpkky1mp2l<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Grindeks koncerna konsolid\u0113tie, provizoriskie finan\u0161u dati liecina, ka 2021. gadu koncerns nosl\u0113dzis ar rekordlielu apgroz\u012bjumu un pe\u013c\u0146u. \u0160aj\u0101 period\u0101 Grindeks koncerna apgroz\u012bjums sasniedza 231,1 milj….<\/p>\n","protected":false},"author":3,"featured_media":6543,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-3381","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/3381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=3381"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/3381\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/6543"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=3381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=3381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=3381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}